EUVIMEDOdkrijte EUVIMED
Randomisierte kontrollierte StudieStudienprotokollOpen access

Short-Term Efficacy of the Artificial Intelligence HeartBot II in Increasing Awareness and Knowledge of Heart Attack in Women: Protocol for a Randomized Controlled Trial With a Waitlist Control

Kurzfristige Wirksamkeit des künstlichen Intelligenz-HeartBot II zur Steigerung von Bewusstsein und Wissen über Herzinfarkt bei Frauen: Protokoll einer randomisierten kontrollierten Studie mit Wartelisten-Kontrollgruppe

Yoshimi Fukuoka iD, Diane Dagyong Kim iD, Jingwen Zhang iD, Thomas J Hoffmann iD, Kenji Sagae iD

JMIR Research Protocols · 2026-08-12 · 15 · e103597-e103597

DOI: 10.2196/103597 ↗

Auf einen Blick

Geplant ist eine randomisierte kontrollierte Studie mit 200 Frauen ab 25 Jahren. Untersucht wird, ob die AI-Chatbot-Schulung HeartBot II das Bewusstsein und Wissen zu Herzinfarkt-Symptomen und Hilfeverhalten verbessert.

Fragestellung

Verbessert die AI-Intervention HeartBot II kurzfristig das Bewusstsein und Wissen zu Herzinfarkt-Symptomen und zum Hilfeverhalten bei Frauen im Vergleich zu einer Wartelisten-Kontrollgruppe?

Methode

Randomisierte kontrollierte Studie mit 1:1-Zuteilung; 200 Frauen ab 25 Jahren; Intervention über 12 Wochen mit 4 Modulen der App; Kontrollgruppe erhält die identische Intervention nach 12 Wochen.

Ergebnisse

Primärer Endpunkt ist die Veränderung von Baseline bis 12 Wochen im 4-Item-Score zur Herzinfarkt-Reaktionsbereitschaft. Ergebnisse liegen im Protokoll noch nicht vor.

Schlussfolgerung der Autor:innen

Nach Kenntnis der Autor:innen ist dies die erste RCT zur strengen Prüfung der Wirksamkeit von AI HeartBot II. Bei Wirksamkeit könnte die Intervention eine skalierbare, zugängliche und kostengünstige Kommunikationsstrategie sein.

Kernaussagen

  • Primärer Endpunkt: Änderung des 4-Item-Scores bis 12 Wochen
  • Intervention: 4 Module in der HeartBot II-App über 12 Wochen
  • Ergebnisse waren bei Einreichung noch nicht verfügbar

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

At a glance

Randomisierte kontrollierte Studie in JMIR Research Protocols, published online on 2026-08-12. Written by Yoshimi Fukuoka and 4 co-authors. Institution: Department of Physiological Nursing, School of Nursing, University of California, San Francisco, 521 Parnassus Ave, San Francisco, CA, 94143, United …. Major MEDLINE topics: Artificial Intelligence, Health Knowledge, Attitudes, Practice, Awareness. 38 references. The full text is freely available in PubMed Central.

Auf einen BlickPovzetekSubjectsBibliografski podatkiCiteRelated studies

Abstract (original language)

Background

Heart disease remains a leading cause of death for women in the United States. Despite this burden, awareness that heart disease is the leading cause of death among women declined from 65% in 2009 to 44% in 2019, with the largest declines observed among Hispanic, Black, and younger women. Thus, innovative, scalable, and cost-effective educational strategies are needed to improve women’s awareness of heart attack symptoms and appropriate care-seeking behaviors.

Objective

This study aims to evaluate the short-term efficacy of the artificial intelligence (AI) HeartBot II, a chatbot-based educational intervention, in improving women’s awareness and knowledge of heart attack symptoms and care-seeking behavior compared with a waitlist control group.

Methods

This randomized controlled clinical trial (RCT) with a waitlist control will enroll 200 women aged 25 or older, who will be randomized using a 1:1 allocation ratio. The intervention group will download the AI HeartBot II app and complete the 4 modules (including information on heart attack symptoms, risk factors, and calling 911) over 12 weeks. The waitlist control group will start receiving an identical intervention at 12 weeks. The primary outcomes will be change from baseline to 12 weeks in a 4-item heart attack response preparedness score, calculated as the mean of 4 self-reported items assessing confidence in recognizing signs and symptoms of a heart attack, distinguishing heart attack symptoms from other medical problems, calling 911 or an ambulance if a heart attack is suspected, and reaching an emergency room within 60 minutes of symptom onset. The primary analysis will estimate the intervention effect using constrained longitudinal data analysis implemented with linear mixed models, including fixed effects for time and time-by-treatment group interaction. Sensitivity analyses for the individual ordinal items will use ordinal logistic mixed-effects models.

Results

We received approval from the University of California, San Francisco, Institutional Review Board (No. 25‐44825) on January 9, 2026, and this trial was registered on ClinicalTrials.gov (NCT07416734) on February 11, 2026, prior to enrollment of the first participant. Recruitment began in April 2026. As of manuscript submission, 86 participants were enrolled. Enrollment is expected to be completed by September 2026, and all follow-up assessments are anticipated to be completed by March 2027. Data analysis is expected to begin in spring 2027, with study results anticipated for publication later in 2027.

Conclusions

To the best of our knowledge, this is the first RCT to rigorously evaluate the efficacy of the AI HeartBot II intervention. If effective, AI HeartBot II could provide a scalable, accessible, and cost-effective public health communication strategy to improve women’s awareness of heart attack symptoms and promote timely care-seeking behaviors in the United States.

Subjects

MeSH terms (MEDLINE)

Artificial IntelligenceHealth Knowledge, Attitudes, PracticeAwarenessHumansFemaleRandomized Controlled Trials as TopicAdult

Author keywords

artificial intelligencechatbotheart diseaseintelligent systemslarge language modelsmachine learningmobile appsnatural language processingrandomized controlled trialwomen

Authors and institutions

  • Department of Physiological Nursing, School of Nursing, University of California, San Francisco, 521 Parnassus Ave, San Francisco, CA, 94143, United States, 1 415476-8419.
  • Department of Communication, University of California, Davis, Davis, CA, United States.
  • Department of Epidemiology & Biostatistics, and Institute for Human Genetics, University of California, San Francisco, San Francisco, CA, United States.
  • Department of Linguistics, University of California, Davis, Davis, CA, United States.

ORCID profiles: Yoshimi Fukuoka, Diane Dagyong Kim, Jingwen Zhang, Thomas J Hoffmann, Kenji Sagae

Cite

APA

Fukuoka, Y., Kim, D. D., Zhang, J., Hoffmann, T. J., & Sagae, K. (2026). Short-Term Efficacy of the Artificial Intelligence HeartBot II in Increasing Awareness and Knowledge of Heart Attack in Women: Protocol for a Randomized Controlled Trial With a Waitlist Control. JMIR Research Protocols, 15, e103597-e103597. https://doi.org/10.2196/103597

Vancouver

Fukuoka Y, Kim DD, Zhang J, Hoffmann TJ, Sagae K. Short-Term Efficacy of the Artificial Intelligence HeartBot II in Increasing Awareness and Knowledge of Heart Attack in Women: Protocol for a Randomized Controlled Trial With a Waitlist Control. JMIR Research Protocols. 2026;15:e103597-e103597. doi:10.2196/103597

BibTeX
@article{Fukuoka2026,
  author = {Fukuoka, Yoshimi and Kim, Diane Dagyong and Zhang, Jingwen and Hoffmann, Thomas J and Sagae, Kenji},
  title = {Short-Term Efficacy of the Artificial Intelligence HeartBot II in Increasing Awareness and Knowledge of Heart Attack in Women: Protocol for a Randomized Controlled Trial With a Waitlist Control},
  journal = {JMIR Research Protocols},
  year = {2026},
  volume = {15},
  pages = {e103597--e103597},
  doi = {10.2196/103597}
}
Start for free →